Amir Heshmatpour Acquires 35,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 35,000 shares of Neonc Technologies stock in a transaction that occurred on Tuesday, September 15th. The stock was bought at an average price of $3.30 per share, with a total value of $115,500.00. Following the purchase, the chief executive officer owned 3,183,000 shares of the company’s stock, valued at $10,503,900. This trade represents a 1.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Neonc Technologies Price Performance

Shares of NASDAQ:NTHI traded down $0.47 during midday trading on Tuesday, reaching $3.31. 285,988 shares of the company’s stock were exchanged, compared to its average volume of 104,731. The company’s 50 day simple moving average is $4.04 and its two-hundred day simple moving average is $5.27. Neonc Technologies Holdings, Inc. has a 12 month low of $3.01 and a 12 month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last posted its earnings results on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Maxim Group started coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They issued a “buy” rating and a $20.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, September 8th. Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Alliance Global Partners assumed coverage on Neonc Technologies in a research report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $16.00.

Key Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies during the 2nd quarter valued at $126,000. BlackRock Inc. bought a new stake in shares of Neonc Technologies in the 2nd quarter valued at about $815,000. Westmount Partners LLC increased its stake in shares of Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Neonc Technologies in the 2nd quarter valued at approximately $1,017,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.